{"id":419,"date":"2023-08-25T14:01:40","date_gmt":"2023-08-25T06:01:40","guid":{"rendered":"https:\/\/consulting-hmk.com\/?p=419"},"modified":"2024-01-18T09:52:31","modified_gmt":"2024-01-18T01:52:31","slug":"anaprazole-sodium-enteric-coated-tablets-approved-for-marketing-by-china-nmpa","status":"publish","type":"post","link":"https:\/\/www.consulting-hmk.com\/fr\/anaprazole-sodium-enteric-coated-tablets-approved-for-marketing-by-china-nmpa\/","title":{"rendered":"Comprim\u00e9s ent\u00e9rosolubles d'anaprazole sodique approuv\u00e9s pour la commercialisation par l'APMN de Chine"},"content":{"rendered":"<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">\u00a0 \u00a0 \u00a0 R\u00e9cemment, le m\u00e9dicament innovant de cat\u00e9gorie 1 Anaprazole Sodium Enteric-coated Tablets (nom commercial chinois : \u5b89\u4e45\u536b) de Xuanzhu (Beijing) Pharmaceutical Technology Co., Ltd. a \u00e9t\u00e9 approuv\u00e9 par l'APMN de Chine. Il s'agit d'un m\u00e9dicament innovant d\u00e9velopp\u00e9 ind\u00e9pendamment en Chine et dot\u00e9 de droits de propri\u00e9t\u00e9 intellectuelle ind\u00e9pendants, indiqu\u00e9 pour le traitement des ulc\u00e8res duod\u00e9naux.<\/span><\/p>\n<p><span style=\"font-size: 14pt;\"><img decoding=\"async\" loading=\"lazy\" class=\"wp-image-412 aligncenter\" title=\"Comprim\u00e9s ent\u00e9rosolubles d&#039;anaprazole sodique approuv\u00e9s pour la commercialisation par l&#039;APMN de Chine\" src=\"https:\/\/consulting-hmk.com\/wp-content\/uploads\/2023\/08\/vecteezy_doctor-hand-with-a-stethoscope-medical-concept__673-300x240.jpg\" alt=\"Comprim\u00e9s ent\u00e9rosolubles d&#039;anaprazole sodique approuv\u00e9s pour la commercialisation par l&#039;APMN de Chine\" width=\"575\" height=\"460\" srcset=\"https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/08\/vecteezy_doctor-hand-with-a-stethoscope-medical-concept__673-300x240.jpg 300w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/08\/vecteezy_doctor-hand-with-a-stethoscope-medical-concept__673-1024x819.jpg 1024w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/08\/vecteezy_doctor-hand-with-a-stethoscope-medical-concept__673-768x614.jpg 768w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/08\/vecteezy_doctor-hand-with-a-stethoscope-medical-concept__673-1536x1229.jpg 1536w, https:\/\/www.consulting-hmk.com\/wp-content\/uploads\/2023\/08\/vecteezy_doctor-hand-with-a-stethoscope-medical-concept__673-2048x1638.jpg 2048w\" sizes=\"(max-width: 575px) 100vw, 575px\" \/><\/span><\/p>\n<p><span style=\"font-family: arial, helvetica, sans-serif; font-size: 14pt;\">L'anaprazole est un inhibiteur de la pompe \u00e0 protons et appartient aux compos\u00e9s benzimidazoles. Il peut inhiber la s\u00e9cr\u00e9tion d'acide gastrique en inhibant l'activit\u00e9 enzymatique de la H+- K+-ATP de la cellule pari\u00e9tale et en r\u00e9duisant la capacit\u00e9 de transport des protons. La mise sur le march\u00e9 de ce m\u00e9dicament offre de nouvelles options th\u00e9rapeutiques aux patients souffrant d'ulc\u00e8res duod\u00e9naux.<\/span><\/p>","protected":false},"excerpt":{"rendered":"<p>R\u00e9cemment, le m\u00e9dicament innovant de cat\u00e9gorie 1 Anaprazole Sodium Enteric-coated Tablets de Xuanzhu (Beijing) Pharmaceutical Technology Co., Ltd. a \u00e9t\u00e9 approuv\u00e9 par l'APMN de Chine. Il s'agit d'un m\u00e9dicament innovant d\u00e9velopp\u00e9 ind\u00e9pendamment en Chine et dot\u00e9 de droits de propri\u00e9t\u00e9 intellectuelle ind\u00e9pendants, indiqu\u00e9 pour le traitement des ulc\u00e8res duod\u00e9naux.<\/p>","protected":false},"author":4,"featured_media":420,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[70],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/posts\/419"}],"collection":[{"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/comments?post=419"}],"version-history":[{"count":0,"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/posts\/419\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/media\/420"}],"wp:attachment":[{"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/media?parent=419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/categories?post=419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.consulting-hmk.com\/fr\/wp-json\/wp\/v2\/tags?post=419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}